Two types of gap phenomena (types I and II ) have been described in human hearts and their electrophysiologic bases have been delineated. In both types of gap phenomena relatively early premature atrial impulses are blocked within some portion of the His-Purkinje system (HPS). By increasing the prematurity of the atrial depolarization, conduction to the ventricles resumes due to delay of the premature impulse with the atrioventricular node (A-VN) (type I gap) or within the proximal HPS (type II gap). Gap phenomena are not observed when the refractory period of the A-VN exceeds that of the HPS. Since atropine decreases refractoriness of the A-V node, its effect on the gap phenomena was studied in nine subjects. T IHE PHENOMENON OF THE GAP in atrioventricular (A-V) conduction has been described in both canine' and human hearts. 2-5 12 In this phenomenon early atrial premature impulses fail to conduct to the ventricles, whereas conduction resumes with still earlier atrial premature impulses. Thus far, two types of gap phenomena in A-V conduction have been described in human hearts and these have been arbitrarily designated as types I and II. During studies designed to evaluate the effects of atropine sulphate on the functional properties of the A-V conducting system, it was noted that the drug consistently decreased refractoriness of the A-V node without affecting refractoriness of the HPS.6 When atropine decreased A-V nodal refractoriness to a smaller value than that of the His-Purkinje system, the setting for the unmasking of gap phenomena was present. The results obtained in nine subjects receiving atropine form the basis of this report.
T IHE PHENOMENON OF THE GAP in atrioventricular (A-V) conduction has been described in both canine' and human hearts. 2-5 12 In this phenomenon early atrial premature impulses fail to conduct to the ventricles, whereas conduction resumes with still earlier atrial premature impulses. Thus far, two types of gap phenomena in A-V conduction have been described in human hearts and these have been arbitrarily designated as types I and II. Common to both types of gaps is that early atrial premature impulses initially block within some part of the His-Purkinje system (HPS); resumption of conduction occurs when earlier premature beats encounter delay proximal to the site of initial block, and thereby allow sufficient time for distal recovery to occur. In type I gap the area of proximal delay occurs within the A-V node3 3 while in type II gap the delay occurs within the proximal portion of the His-Purkinje system (HPS).5 Demonstration of the gap phenomenon depends upon the fact that the effective refractory period (ERP) of some part of the HPS is longer than the functional refractory period (FRP) of the A-V node.
During studies designed to evaluate the effects of atropine sulphate on the functional properties of the A-V conducting system, it was noted that the drug consistently decreased refractoriness of the A-V node without affecting refractoriness of the HPS.6 When atropine decreased A-V nodal refractoriness to a smaller value than that of the His-Purkinje system, the setting for the unmasking of gap phenomena was present. The results obtained in nine subjects receiving atropine form the basis of this report. spectively, whereas no gap in A-V conduction was present in the control period at these same cycle lengths. Figures 1 and 2 provide representative examples of these findings. Figure 1 illustrates that in the control study progressive shortening of the A1A2 interval resulted in progressive prolongation in A-V nodal conduction (A2H2) and eventual block within the A-V node (panels A to D). The ERP of the A-V node was 350 msec (table 2) . At shorter A1A2 intervals (panel D) and up to the point of atrial refractoriness, premature atrial impulses continued to be blocked within the A-V node. Thus, in the control period, the ERP of the A-V node exceeded that of the His-Purkinje system. Panel B of figure 2 demonstrates that, following atropine, there is an enhancement of A-V nodal conduction and premature atrial impulses are blocked within the His-Purkinje system at an H1H2 interval of 425 msec. Upon further shortening of the A1A2 interval (panel C), conduction to the ventricles resumed (type I gap) because the premature atrial impulse encountered sufficient A-V nodal delay so that the resultant H1H2 interval (515 msec) now exceeded the effective refractory period of the HPS. In three subjects (nos. 2, 4, and 9), no gap in A-V conduction was present prior to administration of atropine at atrial cycle lengths of 650, 800, and 600 msec, respectively, whereas after drug administration type II gap occurred at these same basic cycle lengths. In patient no. 4, at an atrial cycle length of 800 msec, the FRP of the A-V node (485 msec) was longer than the effective refractory period of the HPS (table 2) . Following atropine the FRP of the A-V node was decreased (405 msec) to a value less than that of the ERP of the His-Purkinje system (450 msec). The graphic demonstration of a type II gap occurring after atropine is illustrated in figure  3 . Panel B demonstrates that atropine shortened the FRP of the A-V node and allowed the premature atrial impulses to reach some portion of the HisPurkinje system during its ERP. As illustrated in panels C and D, A-V conduction resumed as the A1A2 interval was decreased further. However, resumption of conduction occurred at H1H2 intervals which were less than those associated with the previously blocked atrial impulses (panel B). The mechanism postulated to explain this type of gap is that atropine enhances A-V nodal conduction, 
y2~. H4a50 The electrophysiological basis for type I gap was provided by the clinical studies of Wit et al. 3 In these studies, during the period when no A-V conduction occurred, the nonconducted atrial impulses blocked within the HPS and were associated with H1H2 intervals which were less than or equal to the ERP of the HPS. Also, it was noted that during the period when A-V conduction resumed, premature atrial impulses encountered greater A-V nodal delay and the resultant H1H2 intervals were Gallagher et al. 5 In type II gap the period of no A-V conduction is also characterized by atrial impulses which are blocked within the HPS. However, during the period when A-V conduction resumes, the conducted atrial impulses are associated with H1H2 intervals which are less than prior blocked beats and almost always associated with significantly prolonged H2V2 intervals. It has been postulated that in type II gap the premature atrial impulses are initially blocked in some portion of the distal His-Purkinje system and that during the period of resumed A-V conduction, at shorter H1H2 intervals, the premature atrial impulses encounter delay in the proximal HPS which in turn permits the impulse to arrive at the previously refractory distal area after the latter has recovered. Thus, in the type II gap the proximal HPS functions as the A-V node does in a type I gap.
Ventricular Aberration in the Gap Phenomenon
In type I gap the QRS complexes during the period of resumed A-V conduction may be normal or aberrant depending upon the degree of A-V nodal delay to which the premature impulse is subjected. If the resultant H1H2 interval is greater than the relative refractory period of the HPS, then the QRS complexes will be normal. In type II gap the QRS complexes during resumed A-V conduction are almost always aberrant since proximal delay in the HPS is almost never uniformly distributed throughout the trifascicular conducting system, and some degree of asynchronous recovery of excitability and conduction results. Theoretically, normalization of QRS complexes could occur in type II gap if equal and simultaneous delay occurred along both sides of the conduction system.
Functional Nature of the Gap Phenomenon
The gap phenomenon is seen in those subjects in whom the ERP of some portion of the HPS exceeds the FRP of the A-V node. The gap phenomenon is generally not seen in those subjects in whom the ERP of either the A-V node or atrium exceeds that of the HPS. The ability of small doses of atropine to shorten both the FRP and ERP of the A-V node without directly affecting refractoriness of the HPS permitted a consistent demonstration of the gap phenomenon, and exposed its functional nature. Larger doses of atropine were not used in this study in order to avoid a significant increase in ventricular rate which, by itself, might prevent the demonstration of the gap phenomenon by signfficantly shortening the ERP of the HPS. In this study both types of gap were abolished at short, paced atrial cycle lengths (usually 500 msec or less) in all subjects due to both rate related decreases in the ERP of the HPS and to increased delay of conduction within the A-V node. The latter mechanism is responsible for the abolishment of gaps following the use of sympathetic fl-receptor blocking agents. 3 In some subjects in whom the ERP of the HPS is greater than the FRP of the A-V node, the demonstration of the gap phenomenon is not possible because (1) atrial refractoriness occurs before a sufficient delay in the proximal region can be achieved or (2) the ERP of the A-V node is only slightly less than that of the HPS, and decreasing the A, A2 interval causes block within the A-V node.
In no instance was the change in ERP of the atrium after atropine a significant factor in demonstrating the gap phenomenon in these subjects (table 2) .
For intact human hearts the ERP of the HPS has generally been defined as the longest H, H2 interval at which H2 fails to conduct to the ventricles. 10 The existence of a type II gap ( fig. 5 ) exemplifies the limitations of this functional definition. In type II gap the longest H1H2 interval at which H2 fails to conduct to the ventricles defines the ERP of a distal area within the HPS, whereas it is possible for the ERP of a more proximal part of the HPS to be defined as the longest H1H2 interval at which H11 fails to conduct to the ventricles during a period when actually A-V conduction has resumed. The latter H1H2 interval (i.e., the ERP of the proximal HPS) is less than the former (the ERP of the distal HPS).
